Navigation Links
Chimerix Initiates Phase 1 Study of CMX157
Date:5/13/2010

RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

The Phase 1 dose-escalating clinical study is designed to evaluate the safety, tolerability and pharmacokinetics (PK) of CMX157. Healthy volunteers will receive a single-dose of CMX157 (25 mg, 50 mg or 100 mg), a standard dose of tenofovir (as Viread®) or placebo. In addition to monitoring safety and standard PK parameters in plasma, levels of the active antiviral (tenofovir diphosphate) will be determined in peripheral blood mononuclear cells (PBMCs). These data will provide insight into the potential efficacy of CMX157, as the levels of tenofovir diphosphate in PBMCs associated with the antiviral efficacy of Viread have been documented.

"We are pleased to advance CMX157 into human clinical studies. While advances in HIV treatment have resulted in longer life spans, HIV is known to develop resistance to currently approved agents and significant drug side effects remain an issue for many patients," said Wendy Painter, M.D., MPH, Chimerix's Chief Medical Officer. "We are extremely encouraged by preclinical data that show CMX157 to be highly potent and less toxic than current HIV drugs and believe it has the potential to become an important new antiviral therapy."


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
2. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
3. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
4. Chimerix Joins International Network of Organizations to Cure Malaria
5. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
6. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
7. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
8. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
9. EnVivo Initiates Phase IIb Alzheimers Disease Trial For EVP-6124
10. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
11. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... results of a new study led by George ... evidence that nucleation of ice in small droplets ... water,s behavior at the nanoscale. The formation of ... scientific research question whose answer also has important ... , The crystallization of ice from supercooled water ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, innovative ... Genzyme, a Sanofi company and leading biotech company, recently ... a multi-use facility in the United States. With Door ... this latest order underscores the satisfaction and success the ... device improving doorway access control. , “We recommend ...
(Date:5/21/2013)...  MacroGenics, Inc. today announced that an abstract ... Fc-modified chimeric monoclonal antibody (MAb), in patients with ... be presented at the 2013 Annual Meeting of ... Developmental Therapeutics - Immunotherapy Oral Abstract Session on ... The presentation will describe the results of a ...
(Date:5/21/2013)... 21, 2013 NANONEX CORPORATION, a ... , today announced the successful delivery and installation ... the NX-M200B, to a major Japanese manufacturing company. ... fully-automated, production-ready, advanced nanoimprint lithography tool that has ... and substrate sizes and types. Based on Nanonex ...
Breaking Biology Technology:Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2
... April 26 Veran Medical Technologies announced today that ... at Duke University Medical Center with its FDA-cleared SPiN ... peripheral regions of the lungs to access, biopsy and treat potentially ... , , ...
... SAN DIEGO , April 26 Santaris ... discovery and development of RNA-targeted therapies, today announced that ... candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), ... cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug ...
... SHANGHAI , April 23 ... today announced that it filed its annual report on Form ... the Securities and Exchange Commission.,The annual report can be accessed ... Relations section. WuXi,PharmaTech will provide a hard copy of its ...
Cached Biology Technology:Veran Medical Technologies' First SPiN Drive Installation at Duke Medical Center 2Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 2Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 3Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 4Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol 5WuXi PharmaTech Files 2009 Annual Report on Form 20-F 2
(Date:5/20/2013)... a compound abundant in the Mediterranean diet takes away ... altering a very specific step in gene regulation, this ... die as scheduled. , One way that cancer cells ... them to die on a regular cycle that is ... by Ohio State University researchers, found that a compound ...
(Date:5/20/2013)... 20, 2013) - A novel vaccine study ... groundbreaking research that will be unveiled at the American ... The meeting takes place Monday, May 20 - Wednesday, ... Marina. , "The main goal of a vaccine ... a pathogen that causes the disease", explained Dr. Hemachand ...
(Date:5/20/2013)... New Geology articles posted online ... cover a wide swath of geoscience subdisciplines, including ... and paleobotany. Locations studied include Siberia; the Sumatran ... Apuane, Italy; Ukraine; Mars; and the Southeastern U.S. ... Rubies, jadeite, and plate tectonics;, 2. The clear ...
Breaking Biology News(10 mins):The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3Germ-fighting vaccine system makes great strides in delivery 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11
... University of London celebrates distinguished government scientist Professor Robert ... College this week. Chief Scientific Advisor to the ... notable Queen Mary alumnus, Professor Watson is recognised for ... including ozone depletion and global warming. Professor Peter ...
... University researcher has secured a highly sought-after Leadership award which ... Paola Borri, Cardiff School of Biosciences, is a physicist working ... and physical sciences Now, she has won a 1.1M ... the next five years. This will support her own research, ...
... (VBI) at Virginia Tech have constructed a mathematical and ... to simulate the cellular and molecular changes underlying chronic ... to explore different interactions of cells in the immune ... in the colon, and identify intervention points to perhaps ...
Cached Biology News:Honorary Fellowship awarded to government Chief Scientific Advisor 2Boost for world-leading microscopy project 2Math model of colon inflammation singles out dangerous immune cells 2Math model of colon inflammation singles out dangerous immune cells 3
High voltage electrophoresis power supply...
Rab GDP dissociation inhibitor beta...
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
Biology Products: